Manager Biostatistics, Medical Affairs
Regeneron Pharmaceuticals
Summary
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.
Job description
Discover your role
- Partner with Medical Affairs teams on evidence generation and HTA support.
- Develop protocols, statistical analysis plans, and analysis methodologies.
- Collaborate with Statistical Programming on tables, figures, and listings.
- Analyze clinical trial and non-trial data for program decisions.
- Prepare presentations and reports for teams, management, and regulators.
- Advance innovative statistical methods and deliver training to non-statisticians.
- You bring curiosity to post-hoc analyses and novel evidence-generation approaches.
This role requires
- PhD in Statistics/Biostatistics with 2+ years of pharmaceutical experience, or MS with 4+ years.
- Solid knowledge of statistical methodologies, experimental design, and clinical trial design.
- Ability to code in SAS, R, or Python.
- Experience designing clinical and observational studies.
- Experience with machine learning techniques and causal inference methods.
- Experience developing statistical analysis plans and solving complex statistical problems.
- Experience creating tables, listings, and figures for publications and presentations.
- Strong communication skills for technical and non-technical audiences.
- Ability to collaborate across functions, influence stakeholders, and lead effectively.
- Ability to manage multiple priorities in a fast-paced environment.
- Knowledge of life cycle management strategies preferred; drug development knowledge is a plus.
Requirements
- PhD in Statistics/Biostatistics with 2+ years of pharmaceutical experience, or MS with 4+ years
- Solid knowledge of statistical methodologies, experimental design, and clinical trial design
- Ability to code in SAS, R, or Python
- Experience designing clinical and observational studies
- Experience with machine learning techniques and causal inference methods
- Experience developing statistical analysis plans and solving complex statistical problems
- Experience creating tables, listings, and figures for publications and presentations
- Strong communication skills for technical and non-technical audiences
- Ability to collaborate across functions, influence stakeholders, and lead effectively
- Ability to manage multiple priorities in a fast-paced environment
- Knowledge of life cycle management strategies preferred
- Drug development knowledge is a plus
Benefits
- Annual Bonuses
- Incentive Plans
- Equity Awards
- Pension/Retirement Benefits
- 401(k) Matching
- Health & Wellness Programs
- Fitness Centers
- Medical, Dental & Vision
- Paid Time Off
- Family Support Benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.